Royalty Pharma annual stock-based compensation
2018
2019
2020
2021
2022
2023
2024
2025
Royalty Pharma Stock-Based Compensation Growth & History (RPRX)
Royalty Pharma's stock-based compensation was $289.9M for fiscal 2025.
View full Royalty Pharma company overviewRoyalty Pharma annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $289.9M | $287.6M | +12267.49% |
| 2024 | 2024-12-31 | $2.3M | −$13,000 | −0.55% |
| 2023 | 2023-12-31 | $2.4M | $187,000 | +8.62% |
| 2022 | 2022-12-31 | $2.2M | −$273,000 | −11.17% |
| 2021 | 2021-12-31 | $2.4M | −$3.0M | −54.99% |
| 2020 | 2020-12-31 | $5.4M | $5.4M | — |
| 2019 | 2019-12-31 | $0 | $0 | — |
| 2018 | 2018-12-31 | $0 | — | — |
Royalty Pharma quarterly stock-based compensation
Q2.19
Q3.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $107.1M | $16.3M | +17.96% |
| Q1 2026 | 2026-03-31 | $122.0M | $121.5M | +23587.77% |
| Q4 2025 | 2025-12-31 | $125.8M | $125.2M | +23855.81% |
| Q3 2025 | 2025-09-30 | $72.8M | $72.3M | +13748.29% |
| Q2 2025 | 2025-06-30 | $90.8M | $90.1M | +13228.78% |
| Q1 2025 | 2025-03-31 | $515,000 | −$97,000 | −15.85% |
| Q4 2024 | 2024-12-31 | $525,000 | −$92,000 | −14.91% |
| Q3 2024 | 2024-09-30 | $526,000 | −$55,000 | −9.47% |
| Q2 2024 | 2024-06-30 | $681,000 | $95,000 | +16.21% |
| Q1 2024 | 2024-03-31 | $612,000 | $39,000 | +6.81% |
| Q4 2023 | 2023-12-31 | $617,000 | $34,000 | +5.83% |
| Q3 2023 | 2023-09-30 | $581,000 | −$1,000 | −0.17% |
| Q2 2023 | 2023-06-30 | $586,000 | $77,000 | +15.13% |
| Q1 2023 | 2023-03-31 | $573,000 | $77,000 | +15.52% |
| Q4 2022 | 2022-12-31 | $583,000 | $79,000 | +15.67% |
| Q3 2022 | 2022-09-30 | $582,000 | $77,000 | +15.25% |
| Q2 2022 | 2022-06-30 | $509,000 | −$212,000 | −29.40% |
| Q1 2022 | 2022-03-31 | $496,000 | −$217,000 | −30.43% |
| Q4 2021 | 2021-12-31 | $504,000 | −$336,000 | −40.00% |
| Q3 2021 | 2021-09-30 | $505,000 | −$343,000 | −40.45% |
| Q2 2021 | 2021-06-30 | $721,000 | −$3.0M | −80.72% |
| Q1 2021 | 2021-03-31 | $713,000 | $713,000 | — |
| Q4 2020 | 2020-12-31 | $840,000 | — | — |
| Q3 2020 | 2020-09-30 | $848,000 | $848,000 | — |
| Q2 2020 | 2020-06-30 | $3.7M | $3.7M | — |
| Q1 2020 | 2020-03-31 | $0 | — | — |
| Q3 2019 | 2019-09-30 | $0 | — | — |
| Q2 2019 | 2019-06-30 | $0 | — | — |
Royalty Pharma stock-based compensation trends
Over the last five fiscal years, Royalty Pharma's stock-based compensation increased from $5.4M to $289.9M, a change of $284.5M. The latest reported quarter, Q2 2026, shows $107.1M.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Royalty Pharma source filings ↗